Institution
Virginia Commonwealth University
Education•Richmond, Virginia, United States•
About: Virginia Commonwealth University is a education organization based out in Richmond, Virginia, United States. It is known for research contribution in the topics: Population & Health care. The organization has 23822 authors who have published 49587 publications receiving 1787046 citations. The organization is also known as: VCU.
Topics: Population, Health care, Poison control, Medicine, Cancer
Papers published on a yearly basis
Papers
More filters
••
Medical University of Vienna1, Harvard University2, Technische Universität München3, Mayo Clinic4, National Institutes of Health5, University of Cologne6, University Of Tennessee System7, Gdańsk Medical University8, University of Salamanca9, Virginia Commonwealth University10, Ludwig Maximilian University of Munich11, University of Naples Federico II12
TL;DR: Criteria for diagnosing MCA and related disorders are defined by robust and generally applicable criteria and should assist in the identification and diagnosis of patients with MCAS, and in avoiding misdiagnoses or overinterpretation of clinical symptoms in daily practice.
Abstract: Activation of tissue mast cells (MCs) and their abnormal growth and accumulation in various organs are typically found in primary MC disorders also referred to as mastocytosis. However, increasing numbers of patients are now being informed that their clinical findings are due to MC activation (MCA) that is neither associated with mastocytosis nor with a defined allergic or inflammatory reaction. In other patients with MCA, MCs appear to be clonal cells, but criteria for diagnosing mastocytosis are not met. A working conference was organized in 2010 with the aim to define criteria for diagnosing MCA and related disorders, and to propose a global unifying classification of all MC disorders and pathologic MC reactions. This classification includes three types of ‘MCA syndromes’ (MCASs), namely primary MCAS, secondary MCAS and idiopathic MCAS. MCA is now defined by robust and generally applicable criteria, including (1) typical clinical symptoms, (2) a substantial transient increase in serum total tryptase level or an increase in other MC-derived mediators, such as histamine or prostaglandin D2, or their urinary metabolites, and (3) a response of clinical symptoms to agents that attenuate the production or activities of MC mediators. These criteria should assist in the identification and diagnosis of patients with MCAS, and in avoiding misdiagnoses or overinterpretation of clinical symptoms in daily practice. Moreover, the MCAS concept should stimulate research in order to identify and exploit new molecular mechanisms and therapeutic targets.
509 citations
••
TL;DR: Using density functional theory, it is found that an isolated Li(12)C(60) cluster where Li atoms are capped onto the pentagonal faces of the fullerene not only is very stable but also can store up to 120 hydrogen atoms in molecular form with a binding energy of 0.075 eV/H(2).
Abstract: Solid state materials capable of storing hydrogen with high gravimetric (9 wt %) and volumetric density (70 g/L) are critical for the success of a new hydrogen economy. In addition, an ideal storage system should be able to operate under ambient thermodynamic conditions and exhibit fast hydrogen sorption kinetics. No materials are known that meet all these requirements. While recent theoretical efforts showed some promise for transition-metal-coated carbon fullerenes, later studies demonstrated that these metal atoms prefer to cluster on the fullerene surface, thus reducing greatly the weight percentage of stored hydrogen. Using density functional theory we show that Li-coated fullerenes do not suffer from this constraint. In particular, we find that an isolated Li12C60 cluster where Li atoms are capped onto the pentagonal faces of the fullerene not only is very stable but also can store up to 120 hydrogen atoms in molecular form with a binding energy of 0.075 eV/H2. In addition, the structural integrity ...
509 citations
••
TL;DR: It is shown that targeting oligonucleotides released from programmable microarrays can be used to capture and amplify ∼10,000 human exons in a single multiplex reaction, and it is anticipated that highly multiplexed methods for targeted amplification will enable the comprehensive resequencing ofhuman exons at a fraction of the cost of whole-genome resequenced.
Abstract: A new generation of technologies is poised to reduce DNA sequencing costs by several orders of magnitude. But our ability to fully leverage the power of these technologies is crippled by the absence of suitable 'front-end' methods for isolating complex subsets of a mammalian genome at a scale that matches the throughput at which these platforms will routinely operate. We show that targeting oligonucleotides released from programmable microarrays can be used to capture and amplify approximately 10,000 human exons in a single multiplex reaction. Additionally, we show integration of this protocol with ultra-high-throughput sequencing for targeted variation discovery. Although the multiplex capture reaction is highly specific, we found that nonuniform capture is a key issue that will need to be resolved by additional optimization. We anticipate that highly multiplexed methods for targeted amplification will enable the comprehensive resequencing of human exons at a fraction of the cost of whole-genome resequencing.
509 citations
••
University of Toronto1, German Cancer Research Center2, Dartmouth College3, Boston Children's Hospital4, University of Texas MD Anderson Cancer Center5, Ontario Institute for Cancer Research6, GlaxoSmithKline7, University of British Columbia8, Uniformed Services University of the Health Sciences9, University of Utah10, The Catholic University of America11, Stanford University12, Virginia Commonwealth University13, University of Warsaw14, McMaster University15, Heidelberg University16, University of Michigan17, University of California, San Francisco18, McGill University19
TL;DR: It is concluded that epigenetic modifiers are the first rational therapeutic candidates for this deadly malignancy, which is epigenetically deregulated but genetically bland.
Abstract: Ependymomas are common childhood brain tumours that occur throughout the nervous system, but are most common in the paediatric hindbrain. Current standard therapy comprises surgery and radiation, but not cytotoxic chemotherapy as it does not further increase survival. Whole-genome and whole-exome sequencing of 47 hindbrain ependymomas reveals an extremely low mutation rate, and zero significant recurrent somatic single nucleotide variants. Although devoid of recurrent single nucleotide variants and focal copy number aberrations, poor-prognosis hindbrain ependymomas exhibit a CpG island methylator phenotype. Transcriptional silencing driven by CpG methylation converges exclusively on targets of the Polycomb repressive complex 2 which represses expression of differentiation genes through trimethylation of H3K27. CpG island methylator phenotype-positive hindbrain ependymomas are responsive to clinical drugs that target either DNA or H3K27 methylation both in vitro and in vivo. We conclude that epigenetic modifiers are the first rational therapeutic candidates for this deadly malignancy, which is epigenetically deregulated but genetically bland.
508 citations
••
TL;DR: This study shows that treatment with mepolizumab, an agent designed to target eosinophils, can result in corticosteroid-sparing for patients negative for FIP1L1-PDGFRA who have the hypereos inophilic syndrome.
Abstract: The primary end point was reached in 84% of patients in the mepolizumab group, as compared with 43% of patients in the placebo group (hazard ratio, 2.90; 95% confidence interval [CI], 1.59 to 5.26; P<0.001) with no increase in clinical activity of the hypereosinophilic syndrome. A blood eosinophil count of less than 600 per microliter for 8 or more consecutive weeks was achieved in 95% of patients receiving mepolizumab, as compared with 45% of patients receiving placebo (hazard ratio, 3.53; 95% CI, 1.94 to 6.45; P<0.001). Serious adverse events occurred in seven patients receiving mepolizumab (14 events, including one death; mean [±SD] duration of exposure, 6.7±1.9 months) and in five patients receiving placebo (7 events; mean duration of exposure, 4.3±2.6 months). CONCLUSIONS Our study shows that treatment with mepolizumab, an agent designed to target eosinophils, can result in corticosteroid-sparing for patients negative for FIP1L1– PDGFRA who have the hypereosinophilic syndrome. (ClinicalTrials.gov number, NCT00086658.)
507 citations
Authors
Showing all 24085 results
Name | H-index | Papers | Citations |
---|---|---|---|
Ronald C. Kessler | 274 | 1332 | 328983 |
Carlo M. Croce | 198 | 1135 | 189007 |
Nicholas G. Martin | 192 | 1770 | 161952 |
Michael Rutter | 188 | 676 | 151592 |
Kenneth S. Kendler | 177 | 1327 | 142251 |
Bernhard O. Palsson | 147 | 831 | 85051 |
Thomas J. Smith | 140 | 1775 | 113919 |
Ming T. Tsuang | 140 | 885 | 73865 |
Patrick F. Sullivan | 133 | 594 | 92298 |
Martin B. Keller | 131 | 541 | 65069 |
Michael E. Thase | 131 | 923 | 75995 |
Benjamin F. Cravatt | 131 | 666 | 61932 |
Jian Zhou | 128 | 3007 | 91402 |
Rena R. Wing | 128 | 649 | 67360 |
Linda R. Watkins | 127 | 519 | 56454 |